摘要
近视发生率逐年升高,低龄化趋势明显,近视防控形势十分严峻.巩膜是近视发展的靶向器官,当近视发生和发展时,巩膜组织的超微结构发生病理改变,导致其张力性降低,从而引起眼轴进行性增长和后巩膜的扩张.巩膜胶原交联技术可以有效增加巩膜组织的硬度、抗张力性,在近视防控特别是病理性近视防治方面有很大潜力.目前,巩膜胶原交联技术在病理性近视防治的研究均处于动物实验阶段,且安全性仍有很大的争议,多种因素可影响其安全性.任何一项新技术的开展,安全性是首要条件,全面认识巩膜胶原交联技术在近视防控中的安全性,可以为巩膜胶原交联的进一步研究提供更多的依据和指导.
Abstract
The incidence of myopia is increasing year by year and the trend of younger age is obvious.The situation of myopia prevention and control is very serious.The sclera is the target organ for the development of myopia.When myopia occurs and develops,the ultrastructure of the sclera tissue will undergo pathological changes,resulting in a decrease in its tensile strength,then progressive axial growth and posterior sclera expansion.Scleral collagen cross-linking can effectively increase the hardness and tensile strength of scleral tissue,which may have great potential in the prevention and control of myopia,especially pathological myopia.At present,the effectiveness of scleral collagen cross-linking technology in the prevention and treatment of pathological myopia researches are still in the stage of animal experiments,and there are a lot of controversies on the safety.The development of any new technology to ensure safety is the primary condition.A comprehensive understanding of the safety of scleral collagen crosslinking in the prevention and control of myopia can provide more basis and guidance for the further study of scleral collagen crosslinking.
NETL
NSTL
维普
万方数据